With the mission of addressing patients’ unmet medical needs through innovative theranostics, we are keen to explore various collaboration opportunities in discovery, development, manufacturing and commercialization with partners, such as research institutes of medical isotopes and radiopharmaceuticals, clinical centers, radiopharmaceutical companies, and biopharmaceutical companies from both China and abroad. We are thrilled to build our portfolio through diverse collaboration models including drug translation, co-development, in-licensing, and strategic partnership with leading players. We are continuously integrating resources and enhancing our capabilities to ensure the success of our partnerships.
As a company as well as open platform, we look forward to collaborating with our partners and improve the accessibility and affordability of precision diagnostic & therapeutic radiopharmaceutical solutions for patients in need.
We are actively pursuing strategic cooperation with global radioisotope suppliers for long-term supply of major radioisotopes including 177Lu, 225Ac, 221At, etc.
We are closely monitoring the progress of global investigators’ research and development, and actively seeking new collaborations in drug translations that can maximize the value of investigators’ research work globally and drive the medical evolution.
We are seeking innovative radioligand theragnostic programs at all developmental stages for in-licensing in Greater China region and beyond, with the aim of introducing more accessible radiopharmaceutical products to the patients.
We are embracing all possible opportunities of co-development in potential radioligands and drug candidates, with biotech companies to jointly explore innovative ligands including small molecule drugs, peptides, antibodies and fragments, minibodies, nanobodies, etc.
Our professional radiolabeling technology, CMC and Regulatory expertise, as well as scale-up production enable the development of novel drugs. With tools like molecular imaging and other drug screening and evaluation platforms, we are dedicated to increase the efficiency of discovery and development, and accelerate creation of clinical value.
We always hold an open and can-do attitude to welcome various potential collaborative initiatives or dialogues for exploring new drug and solutions that are more effective and efficient. Pleasecontact us should you have any inquiry or idea for collaborations.
Follow us
